Клинико-патогенетическая роль рецепторов пролиферации пероксисом-альфа в атерогенезе

Понимание роли рецепторов пролиферации пероксисом-альфа (PPAR-α) в атерогенезе представляет не только теоретический интерес, но и имеет большое практическое значение, так как в настоящее время существуют препараты, способные усиливать активность этих рецепторов. Установлено, что активация PPAR-α фибратами приводит не только к значительному снижению уровня триглицеридов крови за счет активации липопротеиновой липазы, но и повышает синтез основных апобелков, входящих в состав липопротеинов высокой плотности (ЛПВП), что способствует усилению обратного транспорта холестерина из хиломикронов и липопротеинов очень низкой плотности в печень. Кроме того, PPAR-α усиливают захват ЛПВП печенью. Помимо этого, имеются данные о способности PPAR-α принимать участие в регуляции процессов воспаления, экспрессии молекул адгезии, выработке факторов хемотаксиса, а также подавлять пролиферацию гладкомышечных клеток и активность фибробластов. Приведенные данные свидетельствуют о том, что PPAR-α принимают непосредственное участие в процессах атерогенеза и их активация может способствовать регрессу атеросклеротических бляшек и значительному снижению кардиометаболического риска.

рецепторы пролиферации пероксисом-альфа, атерогенез, фибраты

1. Wilhelmsen L., Rosengren A., Johansson S., Lappas G. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Göteborg, Sweden // Eur. Heart J. — 1997. — Vol. 18, № 4. — P. 572-581.

2. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators // Nature. — 1990. — Vol. 347, № 6294. — P. 645-650.

3. Aranda A., Pascual A. Nuclear hormone receptors and gene expression // Physiol. Rev. — 2001. — Vol. 81, № 3. — P. 1269-1304.

4. Desvergne B., Michalik L., Wahli W. Transcriptional regulation of metabolism // Physiol. Rev. — 2006. — Vol. 86, № 2. — P. 465-514.

5. Wan Y.J.Y., Cai Y., Lungo W. et al. Peroxisome proliferator-activated receptor α-mediated pathways are altered in hepatocyte-specific retinoid X receptor α-deficient mice // J. Biol. Chem. — 2000. — Vol. 275, № 36. — P. 28285-28290.

6. Sumanasekera W.K., Tien E.S., Davis J.W. 2nd, Turpey R., Perdew G.H., Vanden Heuvel JP. Heat shock protein-90 (hsp90) acts as a repressor of peroxisome proliferator-activated receptor α and PPARy activity // Biochemistry. — 2003. — Vol. 42, № 36. — P. 10726-10735.

7. Ijpenberg A., Tan N.S., Gelman L. et al. In vivo activation of PPAR target genes by RXR homodimers // Embo. J. — 2004. — Vol. 23, № 10. — P. 2083-2091.

8. Cronet P., Petersen J.F., Folmer R. et al. Structure of the PPARα and PPARy ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family // Structure. — 2001. — Vol. 9, № 8. — P. 699-706.

9. Peet D.J., Janowski B.A., Mangelsdorf D.J. The LXRs: a new class of oxysterol receptors // Curr. Opin. Genet. Dev. — 1998. — Vol. 8, № 5. — P. 571-579.

10. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat // Endocrinology. — 1996. — Vol. 137, № 1. — P. 354-366.

11. Fokko Z., Plutzkya J. PPARα in atherosclerosis and inflammation // Biochim. Biophys. Acta. — 2007. — Vol. 1771, № 8. — P. 972-982.

12. Delerive P., Martin-Nizard F., Chinetti G. et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway // Circ. Res. — 1999. — Vol. 85, № 5. — P. 394-402.

13. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation // Blood. — 2003. — Vol. 101, № 2. — P. 545-551.

14. Michael S. The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor // Cell. — 1997. — Vol. 89, № 3. — P. 331-340.

15. Yijun Z. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor // J. Biol. Chem. — 1997. — Vol. 272, № 41. — P. 25500-25506.

16. Xu H.E., Stanley T.B., Montana V.G. et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha // Nature. — 2002. — Vol. 415, № 6873. — P. 813-817.

17. Torchia J., Glass C., Rosenfeld M.G. Co-activators and corepressors in the integration of transcriptional responses // Curr. Opin. Cell. Biol. — 1998. — Vol. 10, № 3. — P. 373-383.

18. Duez H., Lefebvre B., Poulain P. et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation // Arterioscler. Thromb. Vasc. Biol. — 2005. — Vol. 25, № 3. — P. 585-591.

19. Lefebvre P., Chinetti G., Fruchart J.C., Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis // J. Clin. Invest. — 2006. — Vol. 116, № 3. — P. 571-580.

20. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M. et al. PPAR alpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene // Embo. J. — 1996. — Vol. 15, № 19. — P. 5336-5348.

21. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files // Science. — 2001. — Vol. 294, № 5548. — P. 1866-1870.

22. Staels B., Vu-Dac N., Kosykh V.A. et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates // J. Clin. Invest. — 1995. — Vol. 95, № 2. — P. 705-712.

23. Gaw A., Packard C.J., Caslake M.J. et al. Effects of ciprofibrate on LDL metabolism in man // Atherosclerosis. — 1994. — Vol. 108, № 2. — P. 137-148.

24. Vu-Dac N., Chopin-Delannoy S., Gervois P. et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Reverbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates // J. Biol. Chem. — 1998. — Vol. 273, № 40. — P. 25713-25720.

25. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism // Endocr. Rev. — 1999. — Vol. 20, № 5. — P. 649-688.

26. Hansen M.K., McVey M.J., White R.F. et al. Selective CETP inhibition and PPARα agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice // J. Cardiol. Pharmacol. Ther. — 2010. — Vol. 15, № 2. — Р 196-202.

27. Frick M.H., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease // N. Engl. J. Med. — 1987. — Vol. 317, № 20. — P. 1237-1245.

28. Lemieux I., Laperrière L., Dzavik V., Tremblay G., Bourgeois J., Després J.P. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients // Atherosclerosis. — 2002. — Vol. 162, № 2. — P. 363-371.

29. Motojima K., Passilly P., Peters J.M., Gonzalez F.J., Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue — and inducer-specific manner // J. Biol. Chem. — 1998. — Vol. 273, № 27. — P. 16710-16714.

30. Schoonjans K., Watanabe M., Suzuki H. et al. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter // J. Biol. Chem. — 1995. — Vol. 270, № 33. — P. 19269-19276.

31. Mascaro C., Acosta E., Ortiz J.A., Marrero P.F., Hegardt F.G., Haro D. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor // J. Biol. Chem. — 1998. — Vol. 273, № 15. — P. 8560-8563.

32. Aoyama Т., Peters J.M., Iritani N. et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha) // J. Biol. Chem. — 1998. — Vol. 273, № 10. — P. 5678-5684.

33. Marx N., Mackman N., Schönbeck U. et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes // Circulation. — 2001. — Vol. 103, № 2. — P. 213-219.

34. Inoue I., Goto S., Matsunaga T. et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPAR-gamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells // Metabolism. — 2001. — Vol. 50, № 1. — P. 3-11.

35. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells // Circulation. — 1999. — Vol. 99, № 24. — P. 3125-3131.

36. Jackson S.M., Parhami F., Xi X.P., Berliner J.A., Hsueh W.A., Law R.E., Demer L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction // Arterioscler. Thromb. Vasc. Biol. — 1999. — Vol. 19, № 9. — P. 2094-2104.

37. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers // FASEB J. — 1995. — Vol. 9, № 10. — P. 899-909.

38. Delerive P., De Bosscher K., Vanden Berghe W., Fruchart J.C., Haegeman G., Staels B. DNA binding-independent induction of Ikappa B alpha gene transcription by PPARalpha // Mol. Endocrinol. — 2002. — Vol. 16, № 5. — P. 1029-1039.

39. Yokomizo T., Izumi T., Chang K., Takuwa Y., Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis // Nature. — 1997. — Vol. 387, № 6633. — P. 620-624.

40. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control // Nature. — 1996. — Vol. 384, № 6604. — P. 39-43.

41. Sethi S., Ziouzenkova O., Ni H., Wagner D.D., Plutzky J., Mayadas T.N. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha // Blood. — 2002. — Vol. 100, № 4. — P. 1340-1346.

42. Lee H., Shi W., Tontonoz P. et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and IL-8 by endothelial cells // Circ. Res. — 2000. — Vol. 87, № 6. — P. 516-521.

43. Staels B., Koenig W., Habib A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators // Nature. — 1998. — Vol. 393, № 6687. — P. 790-793.

44. Chinetti G., Gbaguidi F.G., Griglio S. et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors // Circulation. — 2000. — Vol. 101, № 20. — P. 2411-2417.

45. Puddu P., Puddu G.M., Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? // Int. J. Cardiol. — 2003. — Vol. 90, № 2-3. — P. 133-140.

46. Zahradka P., Yurkova N., Litchie B., Moon M.C., Del Rizzo D.F., Taylor C.G. Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation // Mol. Cell. Biochem. — 2003. — Vol. 246, № 1-2. — Р 105-110.

47. Nigro J., Dilley R.J., Little P.J. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells // Atherosclerosis. — 2002. — Vol. 162, № 1. — P. 119-129.

48. Gizard F., Amant C., Barbier O. et al. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a // J. Clin. Invest. — 2005. — Vol. 115, № 11. — P. 3228-3238.

49. van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future // Pharm. Res. — 2004. — Vol. 21, № 9. — P. 1531-1538.